Editorial
There are many consequences of the AIDS pandemic for Africa and the world. No one needs to be reminded of the tragic human cost. A poignant image often seen in South Africa's hospitals is of a young woman lying in bed, dying of AIDS, with her mother and child watching over her.
In addition to the lasting human tragedy, which may be counted in orphaned children, the economic consequences for South Africa and similar Southern African countries may be worst in the devastation of professional classes, such as teachers and nurses. Many economically active citizens will be removed from the body politic, but so will many whose lives and labour are not measured in the economy.
Development or the lack of it influences the AIDS pandemic. Expectations for uniform responses to the pandemic by governments grossly oversimplify the problem. In a country as multilayered and complex as South Africa, responses must be different than in others.
Profound interactions exist between currency exchange rates and medical healthcare through drug costs. Fluctuations in the international market value of currencies affect the availability of proprietary drugs that originate from pharmaceuticals in the developed world. Drug costs have been known to rise tremendously, virtually overnight, in some settings due to currency changes alone.
Patents are a curse to the developing world. South Africa has the misfortune to have "first world" status and "first world" patent laws that protect pharmaceutical companies from generic competition on proprietary medicines. South Africa seems to have found a legal way of escaping from this trap, but the government has seemed reluctant to take this route.
The image of old South Africa haunts the new one. The old South Africa was a pariah in political circles, but economically and in terms of the currency it was still acceptable to international business. The new South Africa may have impeccable political credentials, but on the economic front, in the eyes of people who determine where money goes and how it gets there, it is a new kid on the block. It seems not to be relied on to treat large sums of money in its own currency with due regard and responsibility to the sensitivities of the providers of the money.
Devaluations of the currencies of developing countries have beneficial and detrimental consequences for development. They are most probably a consequence of the lack of faith of the wealthy citizens of the developing countries in the ability or will of the new democratic governments to protect the value of the currency in the face of other political imperatives, such as the need to create jobs, and meet the demands for across-theboard salary increases above inflation.
The manufacturing industry, producers of raw export materials, and the tourist trade have done remarkably well since the devaluation of South Africa's currency, the rand. However, skilled professionals, such as teachers, nurses, doctors, accountants, and lawyers, have left South Africa because they can earn more money in real terms in countries that gladly take them as immigrants. Many developed countries seem to have no qualms about depleting the skilled workforce in the developing world. The developing world also does not seem to have the inclination to fight back meaningfully against this onslaught. For example, a counterattack of aggressive recruitment of skilled professionals might not be regarded as politically correct in developing countries. Extreme sensitivity still exists about the possibility of South Africans being deprived of potential employment in their country by hiring skilled workers externally.
Food prices, for which there is also an international market, have inflated due to the devaluation of the currency. This has led to drastic undernutrition of poor people with small and fixed incomes, forcing the government to look at farm and food subsidies, not just as a social issue, but an electoral one.
Internally, the government must respond to inflation and its consequences with close-to-inflation increases in wages, and income tax adjustment. Ways also need to be found (not necessarily expensive) of increasing disbursement to the very poor, to enable them at least to feed themselves and their families. Concern for equity by the "government of the people" is one of the major reasons for the prevarication about introducing antiretroviral therapy (ART). A new treatment cannot be provided through the government until all people who need it will be in a position to get access. However, the only realistic way to introduce ART is to make it initially available at pilot sites. Pilot sites can be used to benefit people living in the vicinity, to learn more about provision of ART in the Southern African setting, and to train health workers to set up satellite or supported centers, thus incrementally spreading the availability of therapy to everyone.
Drugs will help to improve the quality and duration of life for everyone with HIV/AIDS in South Africa. Poor people are just as capable of complying with drug therapy as well-off people. The problem that poor people have with adherence is reaching a point where they can be monitored and receive their treatment every time and at the right time -a problem with health services, pharmacy supplies, and transport resources, rather than of compliance.
People with enough money to pay for the drugs, or to pay medical aid organizations for the drugs, are becoming increasingly common in South Africa. Nearly everyone has problems paying for the laboratory tests that are necessary to properly monitor the infection and its response to treatment. It is possible to find surrogate tests that are reliable and inexpensive. Their relationship to CD4 count and viral load in practice has not been well defined yet. Simple markers such as body weight, and subjective and objective measures of well-being may also prove useful. Antiretroviral treatment of patients with HIV/AIDS may lead to undetectable viral loads, reducing the potential rate of transmission to uninfected sexual partners, and the incidence of HIV. However, the prevalence of resistant strains of HIV will undoubtedly increase, as it has done elsewhere, with the gradual introduction and more widespread use of antiretroviral drugs. Inevitably some treatment will not meet acceptable standards of monitoring and use, leading to suffering in patients and the community. This should not be an excuse for not providing antiretroviral drugs to large numbers of people with AIDS who can and will undoubtedly benefit a great deal from them.
Treatments for HIV/AIDS will undoubtedly continue to follow certain trends: ■ Available agents will become more numerous. ■ More and different combinations of agents will become possible. ■ Side effects and adverse effects will become better understood and managed. ■ The cost of effective treatment will diminish. ■ Treatments will become safer, more efficacious, and less toxic. ■ Treatments and combinations of treatments will become simpler to administer and take. ■ Health workers will gain experience and become more adept at supervising and guiding patients on treatment, and at devising suitable treatment regimens for patients. ■ There will be a drive to develop three or four standard treatment protocols to address the need for therapies readily administerable in the Primary Health Care (PHC) setting; the Directly Observed Therapy (DOT) system may be used to administer these therapies in the PHC setting where it is practical and appropriate. ■ It will be essential to develop ways of monitoring therapeutic response in PHC settings-general wellbeing and body weight are a simple means of monitoring response to therapy, and should not be rejected as insufficient to offer treatment.
Treatment and the management of patients with HIV/AIDS need to accompany a consideration of the risks of infection to healthcare workers. Campaigns are needed to minimize the unnecessary use of sharp instruments, and to use only "safe sharps."
The wider use of antiretroviral drugs will have both beneficial and detrimental effects. The benefit will be lower viral loads in many patients, constituting lower risks to healthcare workers. The detriment will be more patients with resistant strains of HIV, particularly those with advanced disease and high viral loads. Imaginative ways of countering these effects need to be found. ■
